Table 3.

Virologic Response During and After Therapy

Response	Ledipasvir/Sofosbuvir for 8 Weeks (N = 27)
HCV RNA load <LLOQ TND
On therapy, n (%)
Week 1	5 (19)
Week 2	12 (44)
Week 4	22 (82)
End of therapy (week 8), n (%)	25 (92)a
After end of therapy, n (%)
Week 2 (SVR2)	27 (100)
Week 4 (SVR4)	26 (96)b
Week 8 (SVR8)	26 (96)b
Week 12 (SVR12)	27 (100)
Week 24 (SVR24)	26 (96)c
Virologic breakthrough during treatment	0
Relapse in patients with HCV RNA load <LLOQ TND at end of therapy	0

Each instance of SVR and a number indicates the SVR that number of weeks after the date of the last dose of study treatment.

Abbreviations: <LLOQ TND, less than lower limit of quantification target not detected; HCV, hepatitis C virus; SVR, sustained virologic response.

^aThere were 2 subjects that missed the week 8 visit and did not meet imputation criteria.

^bThere were 2 subjects that each had a detectable HCV RNA load (1 at week 4 after therapy and 1 at week 8 after therapy; 74 and 161 IU/mL, respectively). Both achieved undetectable HCV RNA loads at week 4 on therapy and both achieved SVR12.

^cThere was 1 subject that was lost to follow-up after achieving SVR12.